You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Non-Invasive Treatment for Uveitis
SBC: ACIONT, INC. Topic: NDESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
SBC: GLYCOMIRA, LLC Topic: NIDCRDESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss from loss of mandibular anchorage Gingivitis and periodontitis are initiated by chronic infection o ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting G-CSF Analog for Treating ARS
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic D-peptide Inhibitor of HIV Entry
SBC: NAVIGEN, INC. Topic: NIAIDDESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Continuing Development of PPCM Vaginal Contraceptive Microbicide
SBC: YASO THERAPEUTICS INCORPORATED Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this project is to continue development of a novel, dual indication vaginal contraceptive anti-herpes microbicide product containing PPCM. We will conduct all tasks required to generate the Pharmacology/Toxicology and Chemistry Manufacturing and Controls (CMC) information required for IND submission, and outline the early clinical study designs with ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting G-CSF Analog for Treating ARS
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Point-of-Care HIV Antigen/Antibody Diagnostic Device
SBC: MBIO DIAGNOSTICS INC Topic: NIAIDDESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow of the widely used HIV rapid tests. Phase I research ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
HazReady-Online- Device Agnostic- Multi-player Group Simulation Phase II
SBC: INXSOL LLC Topic: NIEHSDESCRIPTION (provided by applicant): Project Summary inXsol proposes to design and demonstrate a web-based, multiplayer small group simulation to support instructor led HazMat worker health and safety training. This product is called HazReady. The use of distributed, low-cost simulation will allow individuals to attain a level of experience in the probable roles at typical incidents and work sites ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
A pocket-sized device for personal exposure level assessment
SBC: TF SENSORS, LLC Topic: NIEHSDESCRIPTION (provided by applicant): A pocket-sized device for personal exposure level assessment Abstract Detecting environmental toxicants is critical for better understanding of the relationship between chemical exposures and many diseases, and for more effective prevention of the related diseases. Due to large variations in the individuals' genetic susceptibility and environmental exposu ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Non-Invasive Treatment for Uveitis
SBC: ACIONT, INC. Topic: NEIDESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of intermediate and posterior uveitis has been either oral medications (with significant systemic side effects) or ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health